Oragenics (OGEN)
Developing an intranasal concussion treatment candidate through outsourced clinical development.
Something off on this page? Send us feedback.
Develops ONP-002, an intranasal neurosteroid-and-device candidate for concussion and mild traumatic brain injury, through outsourced research, manufacturing, and regulatory work. Has no commercial products or revenue and concentrates limited capital on this program.
Develops ONP-002, an intranasal powder neurosteroid paired with a breath-powered nasal device, for concussion and mild traumatic brain injury. The active Phase IIa study in Australia follows a completed Phase I study in healthy subjects; no product is approved for commercial distribution. U.S. IND-enabling work proceeds separately while ONP-001, an earlier potential treatment for Niemann-Pick Disease Type C, remains only partly owned.
Operates as a small, outsourced clinical-stage developer rather than a commercial drug company. Research, clinical operations, manufacturing services, and regulatory work rely largely on third parties, while the vaccine and lantibiotics programs are paused to focus limited capital on ONP-002. Development, regulatory clearance, manufacturing scale, and prospective product sales or licensing income depend on successful clinical progress and partners.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.9M · Total debt $0 · Total assets $5.5M · Shareholders' equity $3.7M
- Revenue
- $0
- Operating income
- −$2.6M
- Net income
- −$2.5M
No dividends on record.
| Institutions20 holders · as of Mar 31, 2026 | 4.22% | 190.4K shares | |
| Strategic holders1 holder · as of Jan 21, 2026 | 9.15% | 412.7K shares | |
| Otherremainder | 86.63% | 3.91M shares |
4.51M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Sabby Management, LLCStrategic | 9.15% | 412,654 | 13Gfiled Jan 21, 2026 ↗ |
Geode Capital Management, LLCInstitution | 1.44% | 65,072 | 13Fas of Mar 31, 2026 |
Pathstone Holdings, LLCInstitution | 1.22% | 55,001 | 13Fas of Mar 31, 2026 |
Two Sigma Securities, LLCInstitution | 0.45% | 20,343 | 13Fas of Mar 31, 2026 |
HRT Financial LPInstitution | 0.41% | 18,672 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Incannex Healthcare
Concussion/TBI drug candidate with acute neuroprotection overlap.
- electroCore
Commercial nVNS device for persistent post-concussion symptoms.
- Nexalin Technology
mTBI care overlap through HALO Clarity deep-frequency stimulation.
- Alpha Cognition
Preclinical mTBI cognitive-recovery program using ALPHA-1062IN.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Oragenics | $0.5176 | −1.22% | $2.3M | — | — | — | — |
| Incannex Healthcare | $3.27 | +0.93% | $39.1M | — | — | 587.3 | +1,566.7% |
| electroCore | $9.60 | +6.08% | $85.7M | — | — | 2.3 | +28.0% |
| Nexalin Technology | $6.44 | +4.04% | $4.5M | — | — | 20.9 | −82.8% |
| Alpha Cognition | $9.32 | +1.58% | $144.7M | — | — | 9.5 | +262.0% |
| Median | — | — | 15.2 | +145.0% |